Editas Medicine Inc (EDIT)
5.365
-0.10
(-1.74%)
USD |
NASDAQ |
Apr 24, 12:27
Editas Medicine Enterprise Value: 123.59M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 123.59M |
| April 22, 2024 | 135.05M |
| April 19, 2024 | 126.05M |
| April 18, 2024 | 130.96M |
| April 17, 2024 | 135.86M |
| April 16, 2024 | 155.50M |
| April 15, 2024 | 174.32M |
| April 12, 2024 | 184.95M |
| April 11, 2024 | 215.22M |
| April 10, 2024 | 219.32M |
| April 09, 2024 | 250.40M |
| April 08, 2024 | 226.68M |
| April 05, 2024 | 226.68M |
| April 04, 2024 | 234.04M |
| April 03, 2024 | 238.13M |
| April 02, 2024 | 238.95M |
| April 01, 2024 | 272.49M |
| March 28, 2024 | 283.95M |
| March 27, 2024 | 285.58M |
| March 26, 2024 | 267.59M |
| March 25, 2024 | 279.04M |
| March 22, 2024 | 288.04M |
| March 21, 2024 | 317.49M |
| March 20, 2024 | 324.86M |
| March 19, 2024 | 310.95M |
| Date | Value |
|---|---|
| March 18, 2024 | 308.49M |
| March 15, 2024 | 342.04M |
| March 14, 2024 | 343.67M |
| March 13, 2024 | 379.67M |
| March 12, 2024 | 381.31M |
| March 11, 2024 | 413.21M |
| March 08, 2024 | 426.30M |
| March 07, 2024 | 400.94M |
| March 06, 2024 | 419.76M |
| March 05, 2024 | 424.67M |
| March 04, 2024 | 488.48M |
| March 01, 2024 | 538.39M |
| February 29, 2024 | 499.94M |
| February 28, 2024 | 582.57M |
| February 27, 2024 | 401.76M |
| February 26, 2024 | 336.31M |
| February 23, 2024 | 315.86M |
| February 22, 2024 | 325.30M |
| February 21, 2024 | 331.85M |
| February 20, 2024 | 326.94M |
| February 16, 2024 | 343.29M |
| February 15, 2024 | 356.38M |
| February 14, 2024 | 324.49M |
| February 13, 2024 | 281.97M |
| February 12, 2024 | 341.66M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
120.36M
Minimum
Apr 12 2023
5.265B
Maximum
Jan 08 2021
1.089B
Average
784.03M
Median
Aug 09 2022
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 93.30B |
| Moderna Inc | 32.70B |
| Amicus Therapeutics Inc | 3.265B |
| Geron Corp | 1.659B |
| Regeneron Pharmaceuticals Inc | 90.68B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.87M |
| Revenue (Quarterly) | 60.05M |
| Total Expenses (Quarterly) | 84.01M |
| EPS Diluted (Quarterly) | -0.23 |
| Profit Margin (Quarterly) | -31.43% |
| Earnings Yield | -38.21% |
| Normalized Earnings Yield | -38.21 |